Relay Therapeutics

It's #BreastCancerAwarenessMonth. Between 20-30% of women initially diagnosed w/ early-stage breast cancer will ultimately develop metastatic breast cancer. At Relay Tx, we are dedicated to advancing our mission of discovering & developing new medicines to help patients in need.

This weekend, we volunteered at Betsy’s Family Camp & Retreat, a New Hampshire-based summer camp for individuals living with CLOVES Syndrome, a type of #vascularmalformation. Thank you to the CLOVES Syndrome Community & Zebra Crossing for organizing a truly memorable weekend.

We're excited to announce that Claire Mazumdar has been appointed to our Board of Directors. As CEO of @BicaraTx, Claire's expertise and perspective as the leader of a late-stage clinical biotech will complement our board well. Welcome, Claire!

Today, we will present updated data for RLY-2608. With >12 months of follow-up, the data continue to show a class-leading profile, boosting confidence in this program as we prepare to initiate the first-ever Phase 3 trial for a selective PI3K⍺ inhibitor. bit.ly/43mgVns

Complex Lymphatic Anomalies, a group of vascular malformations, are chronic, progressive conditions that significantly impact people’s health & quality of life. For #CLAAwarenessDay, we join the @LGDAlliance & the broader CLA community in raising awareness for CLAs.

Last week at #ESMOBreast25: our team connected with physicians and patient advocacy leaders on the upcoming initiation of our Phase 3 clinical trial, ReDiscover-2, of RLY-2608 + fulvestrant in metastatic #breastcancer. Thank you to @myESMO for bringing this community together.

Last week, we welcomed advocate @edwards_linds to share her journey living with CLOVES, a PIK3CA-driven vascular malformation. Her talk was a powerful reminder of the challenges many people living with vascular malformations & progressive #rarediseases face. Thank you, Lindsey!

Rare diseases are more common than many realize, affecting every 1 in 17 people worldwide. On #RareDiseaseDay, we're reminded that the impact of rare diseases is greater than most can imagine. We're committed to advancing research for the unmet needs & care of the rare community.

Today, we announced Q4 & FY24 results & shared the full trial design of the Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced #breastcancer, which will initiate in mid-2025. Details: ir.relaytx.com/news-releases/…

We will present our preclinical work in #vascularmalformations at #VAC2025 today. As we advance our commitment to innovation, we’re preparing to initiate the Phase 1 clinical trial of RLY-2608 in PI3Kα-driven vascular malformations by the end of Q1. Congratulations Fabien & team!

Today, we celebrate nine years of innovation, dedication & impact. A huge thank you to our incredible team of Relayers and the patients, families & investigators who inspire our mission every day. Here’s to the past, the future, and the lives we strive to change - cheers to 9! 🎂

CEO @SanjivKPatel1 looks forward to presenting at #JPM25 as we continue to transform the #drugdiscovery landscape. Details below. We look forward to connecting in San Francisco!

𝘛𝘪𝘥𝘪𝘯𝘨𝘴 𝘰𝘧 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺 🎁 This holiday season, we partnered with @Thehopefactory to assemble bundles for children at local Boston-area hospitals. Each bundle included games related to STEM & the arts, and hopefully lots of 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺.

Today, we announced updated data for RLY-2608 + fulvestrant that continue to demonstrate clinically meaningful progression free survival. We look forward to presenting these data at #SABCS24 today. Find details & register for our 7AM ET conference call: ir.relaytx.com/news-releases/…

We are pleased to announce we will present updated clinical data for RLY-2608 + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic #breastcancer at #SABCS24. More details here. ir.relaytx.com/news-releases/…

We’re pleased to announce we have entered into an exclusive global licensing agreement with @ElevarThera for lirafugratinib, a highly selective irreversible small-molecule inhibitor of FGFR2, in FGFR2-driven cholangiocarcinoma & other solid tumors. ir.relaytx.com/news-releases/…

At Relay Tx, we always gather for lunch. You grab a seat at any table with any colleague from any group. 🦃 Yesterday’s Thanksgiving lunch looked like any other day of the week - with extra gratitude and extra gravy.

Takeaways from our lunch with board member Jami Rubin: ✨Seek out your mentors; they won’t find you ✨Professional confidence takes time: put in the hours & reps ✨Operate from a place of fearlessness Thanks to Imogen Pryce & our ERG, EmpowHER, for organizing an inspiring chat!

Earlier this month, we announced positive interim data for RLY-2608 in HR+/HER2- #BreastCancer. With a 9.2-month median progression free survival and 33% ORR, RLY-2608 has the potential to offer a level of benefit to patients that has not previously been possible with existing…

Today, we announced positive interim data for RLY-2608 demonstrating clinically meaningful progression free survival for RLY-2608 in patients with HR+/HER2- #BreastCancer. President of R&D Dr. Don Bergstrom shares more about the significance of these data below. Tune into our…